Peptoids Attenuating RAGE-Associated Inflammatory Responses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory diseases associated with RAGE, such as Alzheimer's disease, fail to effectively target and modulate RAGE-associated inflammation, leading to inadequate treatment outcomes.
Innovation Solution
Peptoids, specifically designed to attenuate RAGE-associated inflammatory responses, are used to inhibit RAGE expression and cytokine production in cells, thereby reducing inflammation and disease progression by contacting cells with a composition comprising a peptoid segment that reverses or inhibits RAGE expression and cytokine accumulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat RAGE-associated inflammatory diseases, then treatment is provided, but the therapies fail to effectively target and modulate RAGE-associated inflammation leading to inadequate treatment outcomes
Solution Approach 1:
The patent introduces peptoids as intermediary molecules that specifically bind to RAGE and its ligands (such as Aβ, AGEs, and S100 proteins). These peptoids act as mediators that interfere with the pathological interaction between RAGE and its ligands, thereby modulating RAGE-associated inflammation. The peptoids serve as a bridge that disrupts the harmful signaling pathway without directly activating or inhibiting RAGE in a simplistic manner, providing nuanced therapeutic control.
Solution Approach 2:
The patent employs peptoids with specifically optimized parameters including molecular weight (typically 500-2000 Da), hydrophobicity (logP values), and amino acid composition to achieve effective RAGE modulation. By carefully adjusting these parameters, the peptoids can selectively bind to RAGE ligands with appropriate affinity and specificity, enabling effective inhibition of RAGE-associated inflammation while maintaining safety and efficacy.
2Object-generated harmful factors
If peptoids are used to inhibit RAGE expression and cytokine production, then inflammation is reduced, but the mechanism of action requires specific molecular design and optimization
Solution Approach 1:
The patent designs peptoids as segmented molecules composed of repeating amino acid units with specific side chains. Each segment or repeating unit contributes specific functional properties such as hydrophobicity, hydrogen bonding capacity, and steric bulk. This segmentation allows for systematic optimization of peptoid properties by modifying individual units while maintaining the overall structure, thereby reducing the complexity of molecular design through modular approaches.
Solution Approach 2:
The patent systematically varies key parameters of peptoid molecules including the number of repeating units, the type of amino acid side chains (e.g., aromatic, aliphatic, charged), and the overall molecular weight to optimize therapeutic efficacy. By establishing structure-activity relationships and optimizing these parameters, the patent reduces design complexity through rational design principles rather than trial-and-error approaches.
3Adaptability or versatility
If peptoids target multiple RAGE ligands and pathways, then dual-target therapy is achieved, but the specificity and selectivity of action must be maintained
Solution Approach 1:
The patent designs peptoids with universal binding capabilities that allow them to interact with multiple RAGE ligands including Aβ, AGEs, and S100 proteins through common structural features. The peptoids possess universal functional groups and molecular characteristics that enable simultaneous or sequential binding to different ligands, providing dual-target therapy capability. This multi-functionality is achieved while maintaining specificity through careful molecular design.
Solution Approach 2:
The patent incorporates specific local structural features within the peptoid molecules, such as aromatic side chains at particular positions or specific hydrogen bonding motifs, that are responsible for selective binding to different RAGE ligands. By placing specific functional groups at specific locations (local quality), the peptoids achieve high binding specificity for different targets while maintaining overall versatility and dual-target capability.
Data Source
AI summary
Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.